Free peptide has been found to inhibit cytotoxic T lymphocyte (CTL) activity, and veto cells bearing peptide-major histocompatibility complex (MHC) complexes have been found to inactivate CTL, but the two phenomena have not been connected. Here we show that a common mechanism may apply to both. CD8 + CTL lines or clones specific for a determinant of the human immunodeficiency virus (HIV) 1 IIIB envelope protein gp160, P18IIIB, are inhibited by as little as 10 min exposure to the minimal 10-mer peptide, 1-10, within P18IIIB, free in solution, in contrast to peptide already bound to antigen-presenting cells (APC), which does not inhibit. Several lines of evidence suggest that the peptide must be processed and presented by H-2D a on the CTL itself to the specific T cell receptor (TCR) to be inhibitory. The inhibition was not killing, in that CTL did not kill SlCr-labeled sister CTL in the presence of free peptide, and in mixing experiments with CTL lines of different specificities restricted by the same MHC molecule, D a, the presence of free peptide recognized by one CTL line did not inhibit the activity of the other CTL line that could present the peptide. Also, partial recovery of activity could be elicited by restimulation with cell-bound peptide, supporting the conclusion that neither fratricide nor suicide (apoptosis) was involved. The classic veto phenomenon was ruled out by failure of peptide-bearing CTL to inactivate others. Using pairs of CTL lines of differing specificity but similar MHC restriction, each pulsed with the peptide for which the other is specific, we showed that the minimal requirement is simultaneous engagement of the TCR and class I MHC molecules of the same cell. This could occur in single cells or pairs of cells presenting peptide to each other. Thus, mechanistically the inhibition is analogous to veto, and might be called self-veto. As a clue to a possible mechanism, we found that free 1-10 peptide induced apparent downregulation of expression of specific TCR as well as interleukin 2 receptor, CD69, lymphocyte function-associated antigen 1, and CD8. This self-veto effect also has implications for in vivo immunization and mechanisms of viral escape from CTL immunity.
T
he TCR of CD8 + class I MHC molecule-restricted cytotoxic T lymphocytes (CTL) binds a processed antigenic peptide, usually composed of 8-10 amino acids, fitted within the groove of a class I MHC molecule situated on the cell surface (1) . Although peptide added free in solution may bind to the class I MHC molecule of the effector CTL, lysis of peptide-coated CTL by other CTL has been reported unlikely (2) (3) (4) , probably because CTL are resistant to their own cytolytic mediators. Nevertheless, we found that a free peptide of optimal size (I-10: RGPGRAFVTI from HIV-1 gp160 envelope glycoprotein) (5, 6 ) almost completely blocked the specific CTL activity toward targets presensitized with the same peptide when added in solution during the 4-6 h 51Cr release assay. Several recent papers have described similar inhibitory phenomena by free antigenic peptide (7) (8) (9) (10) (11) , but the mechanism of this inhibition is still controversial. Some papers suggest self-destruction (suicide) (8, 9, 12) , some argue CTL-CTL killing (fratricide) (13) , and some indicate a pronounced but transient inhibition or inactivation (anergy) (14) . Also, as Su et al. (13) point out, the requirements for killing may be different from those for anergy. A possibly related phenomenon was seen earlier for CD4 + MHC class II-restricted Th cells, in which exposure of T cell clones to high concentrations ofpeptide for >6 h led to an anergic state lasting at least 7 d, although the cells were not killed because they could still respond to IL-2 (15) (16) (17) . In this case, peptide had to be presented on class II MHC molecules, but did not require APC other than the human class II MHC-positive T cells themselves. However, subsequent studies showed that such anergy induced by antigen presented on T cells was not due to lack of costimulation (18) , and so the mechanism was distinct from that of anergy induced by antigen-MHC complexes in the absence ofcostimulation (19, 20) .
Another situation in which CD8 + CTL are inactivated but not always killed is termed the veto phenomenon (11, (21) (22) (23) (24) . The veto cell is a cell expressing the peptide-MHC complex recognized by the receptor of the CTL, which inactivates the CTL that targets it. Another CD8 § cell is the most effective type of veto cell, but the veto phenomenon does not require engagement of the antigen-specific TCR of the veto cell, only its class I MHC molecules. Recent studies have shown that the CD8 molecule of the veto cell plays a role by binding the o~3 domain of the MHC class I molecule of the CTL being vetoed (24) . This phenomenon has been studied largely in cases of CTL specific for histocompatibility antigens (22) , but recently cells presenting defined peptides have been shown to veto (11) . However, in contrast to the studies of free pepude inhibition of CTL, CTL clones are resistant to the veto phenomenon (23) . Thus, no connection has been made previously between the two phenomena.
In this study, we show that the inhibition of CTL is initiated by the binding of antigenic peptide for which the CTL as specific to the MHC molecules on the CTL's own surface, and is not caused by either the peptide presented only on other cells including saster CTL, or by direct interacnon of the TCR with free peptide. Using pairs of CTL lines of differing specificity but similar MHC restriction, each pulsed with the peptlde for which the other is specific, we show that the minimal requirement is simultaneous engagement of the TCR and class I MHC molecules of the same cell. The transient anergy is associated with downregulation of the TCR and several accessory cell surface molecules.
This mechanism of inhibition characterized here as reminiscent of the veto mechamsm. However, it is not simply the classic veto phenomenon, because CTL presenting the peptide to other CTL do not inhibit them. We suggest that indeed the inhibition by free pepude is analogous at the molecular level to the veto phenomenon, but that CTL clones require a stronger signal through their MHC class l molecules, using a TCR rather than simply CD8 interaction with the c~3 domain. Thus, free peptide inhibition of CTL clones may be considered a process of "self-veto." This self-veto phenomenon may be important not only for in vitro studies, but also in vivo for its possible effect on viral persistence and CTL inactivation by viral products.
Materials and Methods
Animals. CTL Lines and Clones. The CTL hne (LINE-IIIB) and clones specific for the HIV-1 envelope protein of the lllB isolate (gp160IIIB) were generated as described (25) . Both the gpl60lllB-specific CTL line and the clones were restricted by the D a class I MHC molecule and were specific for an immunodominant epltope P18IIIB (RIQRGPGRAFVTIGK). The mlmmal acnve peptide was shown to be the 10-mer, P18-l-10 (5, 6, 26). The CTL line (LINE-MN) specific for the HIV-1 envelope of the MN isolate (gp160MN) was obtained from vMN (gp160MN-expressing recombinant vaccima virus)-immune BALB/c spleen cells (27) . It was stimulated with P18MN (RIHIGPGRAFYT-TKN)-pulsed irradiated syngenelc spleen cells and wath rat ConA supernatant added on the second day and maintained by biweekly repetitive stimulation.
Synthetic Peptides. The peptides are named according to the last amino acid residue and the length, except for the onginal P18IIIB and P18MN peptides. Peptides were synthesized and purified as described previously (25) (26) (27) .
mAbs. The following mAbs were used: ann-CD4 (RL172.4) (28) for deplenng P18IIIB-speclfic I-Aa-resmcted (29) CD4 + Th cell hne (HT-4) (6) and ant~-K k (30) for depleting B10.A spleen cells with rabbit C (Cederlane Laboratones Ltd., Homby, Ontario, Canada); FITC-labeled anti-CD3 (2C1l [31] ), anti-lL2Rc~ (32), anu-CD69 (33), or anti-V[3-8.1 (34) , anti-D a (r domare) (34-2-12 [35] ), anu-L a (30-5-7 [36] ), and anti-K a (31-3-4 [36] ) for cell surface staining.
Inhibition of Serum Actiwty upith Angiotensin-convertmg Enzyme (ACE) Inhibitor. The ACE (EC3.4.15.1 peptidyl/dipeptide hydrolase)-specific inhahitor captopnl (Sigma Chermcal Co., St. Louis, MO) was dissolved in PBS at 100 p,M and added to the culture at 10 -5 M 30 rain before mLxmg with the inhibitory peptide.
CTL Assay. Cytotoxicity was assessed in a standard 5-h SICr release assay as described previously (37) , with StCr-labeled targets, as indicated m the figure legends. SEM oftriphcate cultures was always <5% (and often <3%) of the mean.
FACS ~ Analysis. For direct one-color staining to determine the effect of free peptide treatment of the gp160IllB-specific CTL lines or clones on their surface molecule expression, lff ~ cells were incubated at 37~ for 1 h with free [-10 and then washed three times with RPMI 1640 to remove free peptide. Then, 1 p.g of each indicated FITC-labeled antibody was added to the cell pellet for a 40-rain incubation at 4~ All reagents were pretitered and used in amounts known to be saturating on positive controls. The cells were washed three umes and resuspended at 106 cells/0.5 ml in PBS/BSA/azlde for analysis by FACScan | analyzer (Becton Dickinson Immunochemastry Systems, Mountain View, CA). Dead and damaged cells were excluded from the analysis by propidium Iodide gating.
Results
Free Peptides Inhibit CTL Activities in a Dose-dependem Manner. The minimal epitope of CD8 + CTL lines or clones specific for an immunodominant determinant of the HIV-1 IIIB envelope protein gp160, 18IIIB (315-329) (RIQRGPGRAFVTIGK), presented by the murine class I MHC molecule H-2D d, has been identified as a 10-mer peptide, 1-10 (RGPGRAFVTI) (5, 6, 26) . We have nouced that we could not show a clear concentration dependence when the mimmal size free 1-10 was added together with S~Cr-labeled fibroblast targets during the 4-h assay, al-though the longer peptide, 18IIIB, produced a normal titration curve (Fig. 1 A) . As a possible explanation, when we used peptide-pulsed targets, we observed that free 1-10 strongly inhibited C T L activity even at very low concentrations, whereas the longer peptide, 18IIIB, inhibited the activity only at high concentrations (Fig. 1 A) . Similarly, high concentrations o f free 18IIIB showed some inhibition when used with the unpulsed fibroblast targets. Similar resuits were obtained in five other experiments, including one with 1-10-pulsed targets. Thus, inhibition by free 1-10 superimposed on sensitization o f targets by 1-10 led to a relatively flat net dose-response curve over a wide range, with less net killing than was seen with the longer peptide. Free peptide inhibition could also be observed in another system, using a different epitope (AH2-I9: residues 39-47 from the HIV-1 reverse transcriptase restricted by the K k M H C molecule [data not shown]). These results suggested that free epitopic peptides from the virus may inhibit spe- cific C T L activity against virus-infected targets, and this may be another mechanism o f virus-specific CTL inactivation in vivo. A number o f the experiments detailed below were carried out with both the HIV reverse transcriptase and envelope peptides with similar results, but for simplicity only the envelope peptide experiments are shown.
Titration and Kinetics of 1-10 Treatment for C T L Inhibition.
To further investigate the mechanism o f the inhibition, we pretreated the C T L line or clones with various concentrations of I-10 for 1 h in the absence o f targets, and then added these cells to the assay culture after complete removal o f the free peptide. Profound reduction o f C T L activity was observed when 1-10-specific CTL lines or clones were cocultured briefly with the free minimal peptide 1-10 at >1 v,M, and half-maximal inhibition was achieved at between 0.01 and 0.1 I~M peptide for only 1 h (data not shown). Surprisingly, < 1 0 -m i n pretreatment with 1 I~M o f I-10 appeared to be sutticient to induce inhibition ( Fig. 1 B) . Shorter times could not be investigated because o f the time required for centrifugation and washing. In contrast, although 1 I~M o f the 15-mer peptide 18IIIB showed some inhibitory activity with 1-h pretreatment ( Fig. 1 B) , > 2 h o f treatment was necessary to generate strong inhibition ( tory, in contrast to 1-10, which may bind directly to the surface M H C molecules of the CTL. To confirm this interpretation, we added the dipeptidase inhibitor captopril, which inhibits serum processing o f 18IIIB to 1-10 (26) , together with either 18IIIB or 1-10 in an overnight culture with the CTL line, and found that captopril could abrogate the inhibitory activity of 18IIIB but not 1-10 ( Fig. 2 A) . These findings were reproducible in two additional experiments. Also, since captopril did not affect 1-10 inhibition of CTL activity, it should not be acting at other steps, such as peptide binding to M H C . In addition, inhibition by 18IIIB, but not by 1-10, requires the presence o f FCS (data not shown). Thus, proteolysis o f the 15-mer peptide is necessary for it to inhibit. Also consistent with presentation of processed peptide by D a as a requirement for inhibition, we found that treatment o f CTL with mAbs specific for D a partially prevented the inhibition (data not shown).
CTL Inhibition Can Be Partially Abrogated by Competitive
Peptide. To test whether inhibition required binding of the free 1-10 to the T C R on the CTL and not just to the M H C molecule, we synthesized 1-10 (325(V-Y)) with a single substitution at position 325, which we have identified as the major site for interacting with the T C R (25, 27) . W e have previously demonstrated that HIV-1 IIIB--specific CTL tend to see aliphatic amino acids at position 325, whereas MN-specific C T L see aromatic or cyclic amino acids at this position (38) . This substituted peptide 1-10 (325(V-Y)) could not be recognized by IIIB-specific C T L at all, although it binds to D d because it can he seen by MN-specific C T L with D a (data not shown). Also, studies with sequentially added peptides indicated that the substituted peptide was not an antagonist (39-41) (data not shown). Thus, the peptide cannot interact with the T C R of IIIB-specific C T L despite its binding to the D d class I M H C molecule. As shown in Fig. 2 B, peptide 1-10 (325(V-Y)) did not itself inhibit, but competitively blocked the inhibition induced by 1-10 in a dose-dependent manner during the 4-h CTL assay (Fig. 2 B) . Thus, peptide must bind to both the M H C molecule and the T C R on the CTL to inhibit. Also, since the modified peptide cannot compete for binding to the TCR., this result also confinns that inhibition is mediated by p e p t i d e -M H C complexes and not direct binding of the peptide to the TC1K.
I-lO-pulsed T Cells Did Not Inhibit CTL Activity.
Since free peptide had to bind to the appropriate class I M H C molecule and be presented to the T C R o f the CTL being inhibited, we asked why peptide already bound to D d on fibroblasts did not inhibit. Perhaps the peptide had to be presented on another type o f cell. Therefore, we pulsed 1-10 onto a whole-spleen cell population, chosen to have the same D a molecule but a different H -2 K molecule so that the cells could be depleted afterwards. W e did not observe any inhibition when the C T L were cocultured for 1 h with irradiated B10.A (D d and K k) spleen cells prepulsed with 1-10 and then treated with anti-K k mAb and rabbit C to remove B10.A cells (Fig. 3 A) . Some apparent cold-target inhibition by the peptide-pulsed B10.A cells is eliminated when these are removed. These results were reproducible in three experiments. These data strongly indicated that the free peptide 1-10 does not work via binding to A P C contamination in the CTL line, but only by binding to the CTL themselves. These data also argue against inhibition by veto cells in the spleen, which should inhibit the CTL to which they present peptide.
Failure to see such a veto p h e n o m e n o n is consistent with the resistance of C T L clones to veto (23) .
If the free peptide requires processing so that it can bind to M H C molecules, but does not act when bound to other cells, it may have to be presented by T cells to inhibit. Therefore, we tested the effect ofpresention by other CD4 + or CD8 + T cells. Taking advantage o f the Da-expressing CD4 + helper T cell line, H T -4 (6), 1-10-specific CTL line (LINE-IIIB) cells were mixed with an equal number o f 1-10-pulsed H T -4 or an equal number of 1-10-pulsed LINE-IIIB cells before being added to the 51Cr-labeled Neo*l-10 targets for the 4-h assay culture. In contrast to unpulsed HT-4, 1-10--pulsed H T -4 significantly inhibited the activity o f LINE-IIIB, whereas 1-10-pulsed CD8 + C T L o f the same LINE-IIIB did not (Fig. 3 B) . W e have found that LINE-IIIB did efficiently kill 51Cr-labeled H T -4 cells when pulsed with 1-10, whereas they did not lyse SlCr-labeled 1-10-pulsed LINE-IIIB as targets (data not shown). Thus, we speculated that 1-10-pulsed H T -4 probably acted as cold target inhibitors in the assay culture. Therefore, we depleted the culture of 1-10-pulsed H T -4 cells by treatment with rat anti-mouse C D 4 mAb (R.L174) plus rabbit C after a 2-h incubation with LINE-IIIB, and then added the residual LINE-IIIB to the assay system for an additional 4 h. Depletion o f 1-10-pulsed H T -4 cells completely abrogated the inhibition. This result, reproduced in two additional experiments, suggests that the peptide, 1-10, does not inhibit specific CD8 + C T L when presented by their fellow CD8 + T cells, and the inhibition by 1-10-pulsed CD4 § T cells appears to be by a different mechanism, cold-target inhibition, which does not explain the effect o f free peptide on CTL. This result also excludes a classic veto mechanism, in which CD8 § cells presenting peptide to the T C R o f a CTL inhibit it (11, (21) (22) (23) .
Fratricide May Not Be the Cause of Inhibition.
These results demonstrate that free antigenic peptide must bind to the M H C molecule on the surface o f effector C T L to downregulate their cytolytic activity. T o distinguish whether the mechanism o f inhibition was CTL fratricide, suicide, or anergy induced when the TCP, interacts with a peptide-M H C complex on the surface of the CTL itself, we 51Cr labeled some of the same C T L line as targets and found that they did not kill each other in the presence o f free peptide (data not shown). Moreover, in mixing experiments with two non-cross-reactive CD8 + C T L lines (LINE-IIIB and L I N E -M N ) specific for two homologous peptides, 18IIIB (or 1-10) and 18MN (or MNT10) from different HIV-1 isolates, both presented by the same M H C molecule, H -2 D d, we found that the presence o f free peptide recognized by one CTL line but able to bind to H -2 D a on both CTL lines did not inhibit the cytolytic activity o f the other syngeneic C T L line for its targets, as would be expected if the mechanism had been fratricide (Fig. 4 , reproduced in three additional experiments). Furthermore, M N T 1 0 -prepulsed LINE-IIIB was not inhibited at all when cocultured with L I N E -M N and, conversely, 1-10-prepulsed L I N E -M N was not inhibited when cocultured with LINE-IIIB (see Fig. 5 ). Thus, the mechanism of C T L inhibition by the free epitopic peptide appears not to be fratricide, inhibition by one T cell of another T cell presenting the specific peptide, or the release o f inhibitory cytokines. Rather, it appears that the peptide must be presented on the T cell's own M H C molecules, to the cell's own T C R specific for that peptide-MHC complex.
Dual Engagement Requirement. The possibility remained that simultaneous occupancy o f both the T C R and M H C molecule on the CTL was all that was required, so that two CTL lines specific for different peptides on the same M H C molecule could inhibit each other if each was pulsed with the peptide for which the other CTL was specific and they were washed and mixed. This experiment differs from the previous one in that the C T L presenting one peptide in its 883 Takahashi et al. inhibition in trans appears less efficient than in cis, that is, when the T C R was engaging the peptide-MHC complex on the same cell, but was reproducible and statistically significant. In eight inhibition experiments in four independent studies similar to the one shown in Fig. 5 , the mean percentage of inhibition was 40.3 + 2.69% (P <0.001 by Student's t test). Thus, the mechanism o f inhibition appears to require that both the M H C molecules and the TCP,.s of the CTL be engaged simultaneously ("dual engagement"), either on the same cell or in a conjugate between two or more cells. This dual engagement mechanism is reminiscent of, but distinct from, the veto process (see Discussion).
I-lO-treated CTL Activity Could Be Partially Restored by Restimulation.
If the mechanism o f inhibition were apoptosis o f CTL, cytotoxic activity should not be recovered by restimulation, whereas if it were anergy, activity might be recoverable. Both the downregulated CTL line (Fig. 6 ) and (Fig. 7) . However, class I M H C molecules such as D a (Fig. 7) , K a, or L a (data n o t shown) did n o t show any d o w n m o d u l a t i o n on the 1-10-treated CTL. T h e same pattern of downregulation was seen in five i n d e p e n d e n t experiments, as well as one in which the cells were m a i ntained in suspension (albeit to a slightly lesser extent). It was also observed after 24 h o f exposure to 1-10, and the expression remained partially downregulated 24 h after a 1-h exposure (data not shown). The lack of effect on class I M H C molecules suggests that the FACS | analysis results are not merely caused by downsizing of the cells or a generalized effect o n all surface molecules. Thus, the inhibition of C T L activity is concurrent with a d o w n m o d u l a t i o n of surface activation markers and specific T C R , the latter resembling that reported for C D 4 + class II M H C -r e s t r i c t e d T cells exposed to high concentrations of specific peptide (17) .
Discussion
In this study, we found that exposure of CD8 + CTL to a peptide corresponding to the minimal epitope, free in solution, leads to strong inhibition of the cytolytic activity of the epitope-specific CTL. Our data suggest that this effect requires dual engagement of TCP,. and MHC molecules on the same T cell and involves downregulation of TCR. and several other surface molecules without cell death. Although shown to be distinct from the classic veto mechanism (21-24), which does not act on long-term CTL fines and clones in vitro, the dual engagement requirement is nevertheless rather analogous to the veto mechanism on a molecular level, so that the inhibition by free peptide may be considered a self-veto process, as discussed below.
Several papers have reported that free epitopic peptide can inhibit the specific activities of CD8 + CTL (7) (8) (9) (10) (11) . However, the mechanism of the inhibitaon is still controversial, and previous studies have not examined a dual engagement requirement. Suet al. (13) concluded that the mechanism of inhibitaon by fr~e cognate peptide is "fratricide" rather than "suicide" (8, 9, 12) based on experiments using CTL isolated with the microdrop separation technique using gel agarose. However, although no killing was observed in the isolated cells in microdrops, functional anergy could not be tested. Thus, there is no real discrepancy with our study, in which we observe anergy but not killing, and in which the process appears to be able to occur in single cells. LaSalle et al. (42) observed that anergy required cell contact when peptides presented by class II MHC molecules were used, but it is not clear that the mechanism is the same as described here for class I MHC presentation. If, as our data suggest, either a single cell or two-cell mechanism can occur, one or the other may predominate depending on cell density and peptide concentration. Thus, the differences among the studies may be explained, at least in part, by differences in these parameters. Also, as Suet al. (13) point out, the requirements for anergy may be different from those for cell death. For example, the study demonstrating fratricide was carried out at 107-fold higher peptide concentration than required for 50% tysis of targets, whereas the anergy induction occurred in a peptide concentration range similar to that required for target sensitization (Fig. l A) . Thus, high dose inhibition may be playing a role in some studies and not others, invoking a mechanism different from that of free peptide at lower concentrations.
To investigate fratricide as a mechanism in our system, we used two distract and non-cross-reactive CD8 + CTL lines, LINE-ItIB and LINE-MN, specific for the homologous peptides 1-10 (18IIIB) or MNT10 (18MN), respectively, and restricted by the same class I MHC molecule, H-2D a. We did not detect any ;inhibition when the LINE-IIIB cells were prepulsed or mixed with soluble 18MN or MNTI0 and cocultured with LINE-MN cells that should kill such peptide-pulsed LINE-IIIB cells if the mechanism were fratricide, and vice versa in the reciprocal combinataon. Moreover, when half the CTL line cells were pulsed with the peptide for which they were specific and cocultured with the other half, the cytolytic activity of the unpulsed cells was not inhibited. These results exclude a classic veto mechanism (11, (21) (22) (23) (24) . In addition, we confirmed that 51Cr-labeled 1-10--pulsed CD8 § CTL are not killed by LINE-IIIB, consistent with resistance of CTL to lysis (2-4). We conclude that fratricide is not the mechanism of inhibition in our system. Furthermore, we have shown that 1-10-treated CTL can be restored to almost 80% of their original activity by restimulation 2 d after peptide treatment. This result and the absence of obvious DNA ladders in the treated CTL also strongly suggest that the principal mechanism is not suicide. Taken together, these results suggest that the major mechanism of inhibition, under our conditions, is transient selfinactivation (anergy or paralysis), not cell death. This interpretation is consistent with the downregulation of receptors we observed. However, it should be noted that the difference between cell death and anergy may depend on the state of the CTL in the conditions of the experiment, such as their bcl-2 levels, so that either outcome may be possible under different circumstances, even when the signaling mechanism is the same.
The effect of peptide length may be an important variable not analyzed in previous studies that may explain some differences in results. Here we show that longer peptides, such as 18IIIB, need processing by protease(s) present in FCS that can be inhibited by specific inhibitors such as captopril (26); thus, only the optimal-sized peptide, such as 1-10, caused rapid and strong inhibition of CTL activity, whereas it takes >2 h for the 15-residue peptide 18IIIB to inhibit. Therefore, some discrepancies between studies may be due to use of longer peptides to analyze the inhibitory mechanism. For example, the difference between the FACS ~ analysas data of Robbins and McMichael (10) and ours may come from the length of the peptide used in the assay, in that they demonstrated downmodulation of CD8 but not of IL-2 receptor or TCR in the presence of free 13-mer peptide from influenza nucleoprotein, which required 10 h for inhibition and was more variable, as we have seen for the 15-mer 18IIIB.
To better understand the minimal signaling requirements for free peptide to inhibit, we also studied the efficacy of other APC in inducing the inhibition. First, we found that BALB/c.3T3 fibroblasts expressing 1-10, either externally pulsed or internally synthesized, did not inhibit the activity of specific CD8 § CTL. Second, 1-10-pulsed Dd-expressing whole spleen ceils from B10.A mice, containing a variety of APC, did not affect the CTL activity when the B10.A cells were removed before the SICr-release assay to avoid cold-target blocking. (Since the spleen ceils also contain T cells that could act as veto cells, these results also help to exclude a classic veto cell mechanism [11, [21] [22] [23] [24] .) Third, we found that presentation of 1-10 by the BALB/c CD4 + Th cell line, HT-4, did not inhibit CD8 + CTL, except by cold-target inhibition, which could be eliminated by de-pletion o f the CD4 + cells. In contrast, CTL line cells that could not be killed when pulsed with peptide also did not act as cold targets and did not inhibit. Time-dependent morphological changes in isolated CTL with free peptide (data not shown), similar to the morphological change observed by Walden and Eisen (8) , if indicative o f the same phenomenon, also exclude cold target inhibition by other CTL and suggest action at the single cell level. Thus, presentation of peptide by any other cell does not mimic the effect o f free peptide.
Nevertheless, the data indicate that the free peptide does not act in the free state, but must be presented by a class I M H C molecule. Captopril abrogation o f inhibition by 18IIIB but not 1-10 suggests that the inhibition requires binding of the minimal peptide to the class I M H C molecule on the CD8 + CTL. This conclusion is supported by partial blocking of inhibition by pretreatment of CTL with anti-D d (data not shown) and by the fact that a noninhibitory, nonantagonistic 1-10 variant with a single substitution at a key TCl~-interacting site competed against the inhibitory activity of the unmodified 1-10. The modified peptide could not compete for binding to the TCP, because it had neither agonist nor antagonist activity despite binding to D a. Thus, competition must be for binding to the M H C molecule, a further indication that free peptide has to bind to the M H C molecule to inhibit. Vitiello et al. (7) similarly concluded that the peptide must be presented on the M H C molecule o f the CTL itself from experiments using D brestricted influenza nucleoprotein-specific CTL derived from chimeric mice in which the CTL were o f different genetic origin not expressing D b. However, the fact that C T L -C T L presentation o f peptide did not produce coldtarget inhibition, and the inability of this mechanism to explain the downregulation of multiple surface molecules on the CTL, make cold-target inhibition of a single C T L by its own M H C molecules presenting peptide (7) unlikely. Taken together, these results, which demonstrate a requirement for binding to the class I M H C molecule but exclude presentation on other cells, indicate that the free peptide must be presented on the CTL themselves to induce specific CD8 + CTL inhibition.
H o w then does presentation of the peptide on the CTL's own M H C molecules differ from presentation on the same M H C molecule of another cell? The experiments in which CTL of different specificity but similar M H C restriction, pulsed with each other's peptide, can inhibit each other (Fig. 5) , in contrast to the case in which the peptide for only one of the CTL is present (Fig. 4) , show that the minimal requirement for inhibition is simultaneous occupancy of the TCI< and M H C molecule on the CTL. This double-pulsing experiment of Fig. 5 creates a situation in which the CTL cannot see the peptide on their own M H C molecules, but must see it on another CTL, and yet each CTL has both its M H C molecules and T C P , engaged (Fig.  8 B) . It allows us to conclude that such simultaneous dual engagement o f M H C and TCP,. on the same cell is required. In the normal circumstance with a single CTL line and a single peptide, this situation can occur between pairs of the same CTL at high density incubated with free peptide (Fig. 8 C) , as well as on isolated single cells (Fig. 8 A) . W h e n cells of the same clone are not together at high density, as may often be the case in nature, the single-cell mechanism may be the only one available. Presentation in the same cell is possible because the cell surface is not smoothly convex, but has many projections and invaginations, and independent evidence for such a functional interaction has been obtained (Koenig, S., personal c o m m unication). If a mixture of peptides and CTL specific for them occurs, as during lysis ofvirally infected cells, the situation in Fig. 8 B, as created in the experiment shown in Fig. 5 , may also arise. Thus, our results suggest that the most hkely mechanism of this inhibition may be signal transduction within the C T L by having its TCP,. ligated to its own M H C molecules in cis or in a reciprocal interaction with a sister cell's TCP, and M H C molecules in trans, resuiting in reversible downregulation of surface molecules. Figure 8 . Model of the self-veto or dual engagement mechanism of CTL inactivation by free peptide. The data indicate that the minimal requirements for free peptide to inactivate CTL are simultaneous occupancy of the class I MHC molecule and the TCP-on the same CTL. This may occur in an isolated cell when the TCP, of a cell binds the peptide-MHC complex formed on the same cell (A). Because the cell surface is not smooth, but has many projections and invaginations, TCP,. and MHC molecules on the same cell can easily come into contact. Alternatively, the same simultaneous engagement of TCP, and MHC may occur between two cells. In the experiment shown in Fig. 5 , in which two noncross-reactive CTL lines were pulsed with each other's peptide, it can occur only when two cells of opposite types come together and recognize their peptides on the other cell's MHC molecules (B). However, in the simpler situation with a single CTL and a single free peptide, two sister cells each binding the peptide may inactivate each other (C). Whether the upper single-cell or the lower two-cell mechanism predominates may depend on cell density.
Simultaneous signaling though the TCR and MHC molecule on the same T cell appears to inhibit.
Recendy, signaling though MHC class I, such as by cross-linking with specific antibodies, has been shown to regulate signal transduction though the TCR.--CD3 complex and can lead to inhibition of cellular function (43) , including cytotoxicity (44) , perhaps by prolonging the duration ofa CD3-induced elevation in intracellular Ca 2+ (45) . Sustained increases in intracellular Ca 2 § can often lead to unresponsiveness in CTL (46) ; consequendy, MHC class I modification of TCR-CD3 signals may represent another mechanism for the induction of anergy. T cell signaling through the class I molecule does not depend on the MHC cytoplasmic domain (47) , but instead requires association of class I protein with other cell surface molecules (48, 49) . Most studies of MHC class I signal transduction and regulation of CTL effector function have involved the use of antibodies as an MHC cross-linking agent. In our system, engagement of MHC class I-peptide complex on a CTL instead by a TCR may lead to anergy via MHC class I regulation of TCR signaling events. This mechanism of anergy induction appears to be distinct from that of TCR triggering in the absence ofa costimulatory signal (19, 50) .
The requirement for simultaneous signaling through the TCR and MHC molecule on the same CTL is reminiscent of the molecular mechanism proposed for the veto phenomenon (23, 24) . The TCR of the CTL being vetoed must bind the MHC molecules of the veto cell, and the CD8 molecule of the veto cell binds the o~3 domain of class I MHC molecules of the CTL. Thus, the CTL has both its TCIk and its class I MHC molecules engaged. The dual engagement permitted by free peptide may be a stronger signal through the MHC molecule, involving the interaction of TCR. rather than CD8 with the peptide-MHC complex, and thus may account for inhibition of T cell clones resistant to classic veto. Nevertheless, the requirement for concurrent engagement of both molecules is a clear parallel. We are not aware of any previous connection made between free peptide inhibition and the veto phenomenon, but on the basis of the results presented here, we propose that free peptide inhibition of CTL activity is actually a process of self-veto.
There are a number of potential mechanisms of inhibition of virus-specific CTL in HIV-l-infected patients. We have observed a similar inhibitory effect of free peptide in vivo in primed animals (Takahashi, H., and Y. Nakagawa, unpublished observations), and Walden and Eisen (8) also observed a similar loss of CTL activity in spleen cells of primed animals after injection of an OVA peptide. Perhaps when vitally infected cells are lysed and the digested intracellular proteins released into the environment of the T cell, anergy may be induced and clearance of the virus from other infected cells prevented. Thus, the self-veto mechanism shown here may contribute to inactivation of virusspecific CTL in vivo and virus persistence, and, conversely, restoration of such inactivated CTL may prevent virus spread and disease progression.
